Newsroom

Our central location for research news and other stories of related information can be found here.

Tuesday, December 11, 2012

First Synergy stents implanted in EVOLVE II trial

The first procedures to implant the novel Synergy bioabsorbable polymer drug-eluting stent as part of the EVOLVE II trial were recently performed at The Christ Hospital in Cincinnati. The procedures were performed by Thomas Broderick, MD, and Joseph Choo, MD, interventional cardiologists at the hospital.

Read The Full Article. (Click Here)

Monday, December 3, 2012

THE CHRIST HOSPITAL ON CUTTING EDGE OF NEW STENT TECHNOLOGY; IMPLANTS INVESTIGATIONAL NEW DEVICE

CINCINNATI, Ohio – December 3, 2012 – Clinical scientists at The Christ Hospital’s Lindner Research Center are leading a worldwide study evaluating new breakthrough coronary stent technology that may make stenting easier and safer.

Read The Full Article. (Click Here)

Monday, September 24, 2012

Dr Sarembock on trans-catheter aortic valve replacement (TAVR)

Nearly one in every eight Americans aged 75 and older will be diagnosed with valvular heart disease. Open-heart surgery has traditionally been the standard approach to treating this increasingly prevalent disease. But many elderly patients cannot undergo the rigors of conventional surgery, creating an urgent need for less invasive, non-surgical solutions for valve disease patients. On 10th September, Dr Sarembock gave our team some of his precious time in explaining the TAVR procedure.

Read The Full Article. (Click Here)

Monday, April 16, 2012

ACC: Novel therapy lowers LDL-C by 72%

A novel monoclonal antibody lowered low density lipoprotein cholesterol (LDL-C) up to 72 percent in patients with primary hypercholesterolemia in a randomized, double-blind, placebo-controlled trial. The results were announced March 26 at the American College of Cardiology’s 61st scientific session and simultaneously published online in the Journal of the American College of Cardiology.

“This was a very sophisticated trial that gleaned a lot of information,” said co-author Dean J. Kereiakes, MD, medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, in an interview. The study was designed to test the safety and efficacy of the human monoclonal antibody SAR236553/REGN727.

Read the Full Article. (Click Here)

Watch the Video. (Click Here)

After an Unprecedented Request for a Retraction, A Close Look at the Data

Guest Post from Edward J. Schloss, MD, the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati, OH.

Last week, St. Jude Medical took the unusual step of requesting a retraction of an article accepted for publication in Heart Rhythm Journal. In this article Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads, Dr. Robert Hauser et al analyzed patient deaths in the FDA MAUDE database associated with St. Jude Medical and Medtronic ICD leads. This week, Dr. Douglas Zipes, Heart Rhythm editor, declined that request. (Please see my previous Cardiobrief coverage of Hauser’s article.)

Read the Full Article. (Click Here)

Friday, April 13, 2012

Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study

Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. /quotes/zigman/233680/quotes/nls/mdt MDT -1.16% announced today the start of the Medtronic IN.PACT SFA II study, the company’s first U.S. clinical trial for its line of IN.PACT drug-eluting balloons.

The first patients in this landmark study were treated this week by Dr. Ash Jain at Washington Hospital in Fremont, Calif., and Dr. Brian Bigelow at St. Vincent Hospital in Indianapolis; Dr. Monica Hunter at Christ Hospital in Cincinnati is planning to treat a patient in the study as early as next week. Drs. Jain, Bigelow and Hunter are the principal investigators at their respective trial site.

Read the Full Story. (PDF)

Thursday, March 8, 2012

Researchers Explore Novel Technology Approach for Uncontrolled High Blood Pressure

A radically different approach to treating high blood pressure – using a minimally invasive procedure– is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

Read the full story. (PDF)

Friday, March 2, 2012

Report from the Riata ICD Lead Summit

Edward J. Schloss, the medical director of cardiac electrophysiology at the Christ Hospital in Cincinnati, OH, attended the Riata ICD Lead Summit in January. Dr. Schloss has forwarded his summary of the meeting to CardioBrief.

Read the Full Summary.

Friday, February 24, 2012

New Stent Researched at Lindner Research Center Now Provides New Benefit to Coronary Artery Disease Patients

The Christ Hospital is the first hospital in Greater Cincinnati to use the Resolute Integrity Drug-Eluting Stent (DES) from Medtronic for the treatment of coronary artery disease (CAD) in multiple patient types. The new device has been shown in a global series of clinical studies to yield consistently excellent results across a broad spectrum of patients. The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) was actively involved in the research and development of this stent through the Resolute U.S. trial. James Kong, M.D., cardiologist with the Ohio Heart and Vascular Center, treated the first patient in Greater Cincinnati.

Read the full story. (PDF)

Thursday, February 9, 2012

Clinical Trial of Next Generation Heart Valve Device Expanded

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital have enrolled and treated the first three patients in the U.S. in the randomized Cohort A of the PARTNER II Trial. This trial, sponsored by Edwards Lifesciences, is studying the company's next-generation Edwards SAPIEN XT transcatheter heart valve in the treatment of aortic stenosis.

Read the full story. (PDF)